<DOC>
	<DOCNO>NCT00231530</DOCNO>
	<brief_summary>The purpose study determine efficacy safety topiramate compare placebo obese , Type 2 diabetic patient control diet .</brief_summary>
	<brief_title>A Study Safety Efficacy Topiramate Treatment Obese , Type 2 Diabetes Patients Controlled Diet</brief_title>
	<detailed_description>Topiramate approve treatment obesity . This randomized , double-blind , placebo-controlled study evaluate efficacy safety topiramate obese , diet-controlled , type 2 diabetic patient . Patients randomize receive either topiramate placebo . After 5 week pre-enrollment phase follow 6 week run-in phase , patient topiramate group start 8-week titration phase reach assign dose topiramate , either 96 192 mg daily . Treatment continue 1 year . Assessments effectiveness include percent change body weight , hemoglobin type A1c [ HbA1c ] level , Body Mass Index [ BMI ] , number proportion 5 % 10 % weight loss responder , glucose tolerance , waist hip circumference , change mass left ventricle heart , blood pressure , fast lipid profile . Safety evaluation , include incidence adverse event , vital sign , clinical laboratory value , electrocardiogram [ ECGs ] , monitor throughout study . The study hypothesis topiramate , combine control diet , effective weight reduction control blood sugar level well tolerate . During initial 8 week , oral dos either match placebo topiramate gradually increase target dos ( 96 milligram [ mg ] 192mg daily ) ; dose maintain 1 year .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<criteria>Body Mass Index &gt; = 27 &lt; 50 Diagnosis Type 2 diabetes accord either Swedish guideline American Diabetes Association ( ADA ) criteria HbA1c &lt; 10.5 % enrollment No previous oral antidiabetic medication insulin therapy Stable body weight Female patient must postmenopausal least 1 year , surgically incapable childbearing , practice acceptable method contraception ( require negative pregnancy test ) Known contraindication hypersensitivity topiramate Fasting plasma glucose ( FPG ) &gt; = 13.1 millimolesl/liter ( 240 milligrams/deciliter ) baseline , Visit 4 ( Week 0 ) HBA1c &gt; 10.5 % enrollment History severe recurrent hypoglycemic episode prior study entry Use systemic corticosteroid within 30 day enrollment Diagnosed Type 1 diabetes History significant cardiovascular disease , uncontrolled thyroid disease , kidney stone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Obesity</keyword>
	<keyword>Diabetic Diet</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Hyperlipidemia</keyword>
	<keyword>Adult-Onset Diabetes Mellitus ( AODM )</keyword>
</DOC>